FDA Delays Cost Trillions: Experts Warn of China's Rise

Economist Tomas Philipson has highlighted the significant economic toll of the U.S. Food and Drug Administration's protracted drug approval timelines. He estimates that a decade is often required from start to finish, with most of this duration dedicated to effectiveness trials rather than safety assessments.

A recent report suggests that reducing FDA effectiveness-review timelines by just one year could generate over $10 trillion in economic value. This acceleration would expedite patient access to new treatments and stimulate further medical innovation.

Philipson further argued that faster approvals could foster greater competition among drug manufacturers, potentially leading to lower drug costs for consumers. The report indicates that shortening approval times by one to six years could yield trillions through earlier access to drugs, biologics, and medical devices.

Critically, the United States faces a competitive challenge from China's swifter and more cost-effective clinical trial system, which could divert crucial investment and development activities. Philipson urged policymakers to reconsider the pace of FDA approvals, drawing a parallel to the urgency seen during Operation Warp Speed for COVID-19.

Proposed reforms include greater integration of artificial intelligence in reviews, optimized clinical trial designs, and expanded access to "right to try" programs.